Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2021 - 2025)

Kiniksa Pharmaceuticals International's Operating Expenses history spans 5 years, with the latest figure at $182.4 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 28.57% year-over-year to $182.4 million; the TTM value through Dec 2025 reached $600.3 million, up 28.04%, while the annual FY2025 figure was $600.3 million, 28.04% up from the prior year.
  • Operating Expenses reached $182.4 million in Q4 2025 per KNSA's latest filing, up from $156.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $182.4 million in Q4 2025 to a low of $42.8 million in Q3 2021.
  • Average Operating Expenses over 5 years is $88.5 million, with a median of $76.3 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: decreased 3.98% in 2022, then surged 70.24% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $54.9 million in 2021, then increased by 1.75% to $55.8 million in 2022, then soared by 49.21% to $83.3 million in 2023, then skyrocketed by 70.24% to $141.8 million in 2024, then increased by 28.57% to $182.4 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Operating Expenses are $182.4 million (Q4 2025), $156.8 million (Q3 2025), and $136.6 million (Q2 2025).